XINGANJIANG
873167
INNOVATIVE DATA
835305
CHENGUANG MEDICAL
430300
4
Hangzhou Gaoxin Materials Technology
300478
5
Beijing Philisense Technology
300287
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 28, 2024 | (Q2)Jun 29, 2024 | (Q1)Mar 30, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jul 1, 2023 | (Q1)Apr 1, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -8.02%3.24B | 4.62%849.84M | -9.07%807.69M | -9.81%812.65M | -16.41%771.03M | 7.37%3.52B | -14.14%812.29M | -10.62%888.24M | 30.11%901M | 922.4M |
Operating revenue | -8.02%3.24B | 4.62%849.84M | -9.07%807.69M | -9.81%812.65M | -16.41%771.03M | 7.37%3.52B | -14.14%812.29M | -10.62%888.24M | 30.11%901M | --922.4M |
Cost of revenue | -13.42%1.75B | -1.08%462.58M | -16.37%435.87M | -15.48%436.83M | -19.49%419.21M | 7.46%2.03B | -13.65%467.61M | -16.23%521.17M | 35.26%516.83M | 520.71M |
Gross profit | -0.73%1.49B | 12.35%387.26M | 1.29%371.83M | -2.17%375.82M | -12.41%351.82M | 7.25%1.5B | -14.79%344.68M | -1.24%367.07M | 23.77%384.17M | 401.69M |
Operating expense | -1.53%1.05B | 27.67%336.08M | 0.63%235.58M | 2.60%278.37M | -21.75%234.23M | 16.54%1.07B | 0.95%263.23M | -34.39%234.1M | 77.99%271.31M | 299.35M |
Selling and administrative expenses | -3.97%553.29M | 49.52%216.33M | -6.55%108.46M | 4.70%152.43M | -33.95%112.19M | 6.02%576.19M | 3.90%144.68M | -48.75%116.05M | 60.55%145.6M | --169.87M |
-General and administrative expense | --553.29M | ---- | ---- | --152.43M | ---- | ---- | ---- | ---- | ---- | ---- |
Research and development costs | 13.99%316.11M | 20.54%81.45M | 21.09%80.9M | 15.28%81.89M | -0.04%71.88M | 21.10%277.31M | -0.70%67.57M | 2.80%66.81M | 44.23%71.03M | --71.91M |
Depreciation amortization depletion | -15.05%182.2M | -24.87%38.3M | -9.78%46.23M | -19.44%44.05M | -12.88%50.16M | 48.99%214.48M | -4.64%50.98M | -21.59%51.24M | 337.65%54.68M | --57.57M |
-Depreciation and amortization | -15.05%182.2M | -24.87%38.3M | -9.78%46.23M | -19.44%44.05M | -12.88%50.16M | 48.99%214.48M | -4.64%50.98M | -21.59%51.24M | 337.65%54.68M | --57.57M |
Operating profit | 1.28%435.12M | -37.17%51.18M | 2.46%136.24M | -13.65%97.45M | 14.91%117.59M | -10.49%429.62M | -43.35%81.45M | 793.10%132.97M | -28.56%112.86M | 102.34M |
Net non-operating interest income expense | 30.97%-207.85M | 18.64%-50.52M | 33.30%-50.42M | 33.18%-52.53M | 35.89%-54.38M | -44.09%-301.12M | 24.28%-62.1M | 8.65%-75.59M | -150.79%-78.61M | -84.82M |
Non-operating interest income | -34.55%7.37M | -63.59%1.97M | -43.98%1.25M | -49.63%1.16M | 125.96%2.99M | 204.74%11.26M | 231.68%5.4M | 59.57%2.23M | 250.00%2.3M | --1.33M |
Non-operating interest expense | -31.10%215.22M | -22.24%52.49M | -33.61%51.67M | -33.64%53.69M | -33.40%57.37M | 46.88%312.38M | -19.29%67.5M | -7.52%77.82M | 152.83%80.91M | --86.15M |
Other net income (expense) | 114.59%94.78M | 1,389.13%111.83M | 100.81%212K | -79.82%29.68M | 83.04%-14.29M | 284.61%44.17M | 117.87%7.51M | -103.52%-26.16M | 1,628.54%147.03M | -84.21M |
Gain on sale of security | -34.75%-7.71M | -200.45%-5.52M | 142.84%2.11M | 31.71%-2.65M | 31.61%-1.64M | 75.18%-5.72M | 5.29%5.5M | 63.85%-4.93M | 61.33%-3.89M | ---2.4M |
Special income (charges) | 106.84%104.49M | 4,455.05%116.84M | --0 | -78.80%31.86M | 85.89%-11.55M | 1,636.87%50.52M | 343.82%2.57M | -814.77%-20.45M | --150.27M | ---81.88M |
-Less:Restructuring and merger&acquisition | ---53.16M | ---- | ---- | 88.55%-17.72M | ---- | ---- | ---- | ---- | ---154.75M | ---- |
-Less:Impairment of capital assets | -115.19%-17.5M | -267.72%-17.5M | --0 | --0 | --0 | --115.22M | --10.43M | --15.91M | --0 | --88.87M |
-Less:Other special charges | 96.57%-5.69M | 89.25%-18.03M | ---- | -82.24%796K | 265.11%11.55M | -5,142.11%-165.73M | -16,045.91%-167.75M | 102.77%4.53M | --4.48M | ---7M |
-Gain on sale of business | --28.15M | --28.15M | --0 | --14.94M | ---- | ---- | ---- | --0 | ---- | ---- |
Other non- operating income (expenses) | -218.12%-2M | 194.01%518K | -142.53%-1.9M | -26.48%472K | -1,833.33%-1.09M | -126.26%-629K | 23.58%-551K | -125.98%-783K | 50.35%642K | --63K |
Income before tax | 86.51%322.05M | 318.82%112.49M | 175.54%86.03M | -58.85%74.6M | 173.36%48.93M | -30.12%172.67M | -58.81%26.86M | 138.68%31.22M | 54.93%181.29M | -66.7M |
Income tax | 436.76%28.33M | 188.75%10M | 485.05%8.19M | 140.56%6.69M | -83.90%3.46M | -122.05%-8.41M | -244.73%-11.26M | 69.68%-2.13M | -194.14%-16.49M | 21.47M |
Earnings from equity interest net of tax | -125.36%-933K | -71.03%-248K | -88.49%-262K | -66.92%-217K | ---206K | ---414K | ---145K | ---139K | ---130K | --0 |
Net income | 62.06%292.79M | 169.22%102.24M | 133.60%77.58M | -65.75%67.7M | 151.34%45.27M | -13.52%180.67M | -33.87%37.98M | 145.06%33.21M | 98.66%197.65M | -88.17M |
Net income continuous Operations | 62.06%292.79M | 169.22%102.24M | 133.60%77.58M | -65.75%67.7M | 151.34%45.27M | -13.52%180.67M | -33.87%37.98M | 145.06%33.21M | 98.66%197.65M | ---88.17M |
Minority interest income | ||||||||||
Net income attributable to the parent company | 62.06%292.79M | 169.22%102.24M | 133.60%77.58M | -65.75%67.7M | 151.34%45.27M | -13.52%180.67M | -33.87%37.98M | 145.06%33.21M | 98.66%197.65M | -88.17M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 62.06%292.79M | 169.22%102.24M | 133.60%77.58M | -65.75%67.7M | 151.34%45.27M | -13.52%180.67M | -33.87%37.98M | 145.06%33.21M | 98.66%197.65M | -88.17M |
Basic earnings per share | 60.33%1.94 | 172.00%0.68 | 131.82%0.51 | -65.91%0.45 | 150.85%0.3 | -17.69%1.21 | -35.90%0.25 | 144.00%0.22 | 80.82%1.32 | -0.59 |
Diluted earnings per share | 60.83%1.93 | 168.00%0.67 | 131.82%0.51 | -65.65%0.45 | 150.85%0.3 | -17.81%1.2 | -34.21%0.25 | 144.00%0.22 | 79.45%1.31 | -0.59 |
Dividend per share | 0.00%0.4 | 0.00%0.1 | 0.00%0.1 | 0.00%0.1 | 0.00%0.1 | 0.00%0.4 | 0.00%0.1 | 0.00%0.1 | 0.00%0.1 | 0.1 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |